바이오베터 시장, 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Biobetters Market was valued at USD 52.8 billion in 2023 and will grow at an 8.3% CAGR between 2024 and 2032, attributed to the rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. As these conditions become more common, there is an increased demand for advanced treatments that offer enhanced efficacy and improved patient outcomes. Innovations in biotechnology, including advancements in protein engineering and drug delivery systems, enable the development of biobetters with superior therapeutic profiles compared to existing biologics. This combination of growing medical needs and technological progress will propel the market expansion.

The biobetters industry is segregated on the basis of drug class, application, route of administration, distribution channel, and region.

The monoclonal antibodies biobetters segment garnered USD 38.5 billion in 2023, propelled by their significant therapeutic potential and widespread use. Monoclonal antibodies are crucial in treating various diseases, including cancers and autoimmune disorders. Improved versions of these antibodies offer enhanced efficacy, a longer half-life, and reduced side effects, which drive their demand. As the market continues to expand, the focus on developing more effective and targeted monoclonal antibody therapies will reinforce this segment's dominance.

The hospital pharmacies segment held USD 25.2 billion in 2023, primarily due to their central role in administering complex biological treatments. Hospital pharmacies are equipped to handle the specialized storage and handling requirements of biobetters, such as monoclonal antibodies and other advanced therapies. Additionally, these facilities are crucial for managing patient-specific dosing and providing expert support for drug administration. As the use of biobetters grows, hospital pharmacies will continue to be a key segment, supporting the distribution and optimal use of these advanced treatments.

North America biobetters market will generate USD 44.1 billion by 2032 due to its advanced healthcare infrastructure, high prevalence of chronic diseases, and strong focus on biotechnology innovation. The region's well-established pharmaceutical industry and ample investment in research and development contribute to the development and adoption of biobetters. Besides, favorable regulatory environments and high healthcare spending further drive market growth. As North America continues to lead in technological advancements and therapeutic innovations, it remains a key contributor to the biobetters industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Enhanced therapeutic effectiveness and reduced side effects
    • 3.2.1.2 Rising prevalence of chronic disease
    • 3.2.1.3 Growing investment in research and development of biobetters
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development costs
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTLE analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Erythropoietin biobetters
• 5.3 Insulin biobetters
• 5.4 G-CSF biobetters
• 5.5 Monoclonal antibodies biobetters
• 5.6 Antihemophilic factor
• 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cancer
• 6.3 Diabetes
• 6.4 Renal disease
• 6.5 Neurodegenerative disease
• 6.6 Genetic disorders
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Subcutaneous
• 7.3 Intravenous
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Amgen Inc.
• 10.3 AstraZeneca PLC
• 10.4 Biogen Inc.
• 10.5 Bristol-Myers Squibb Company
• 10.6 Celltrion Inc.
• 10.7 Eli Lilly And Company
• 10.8 F. Hoffmann-La Roche Ltd.
• 10.9 GSK plc
• 10.10 Kiniksa Pharmaceuticals, Ltd.
• 10.11 Merck and Co., Inc.
• 10.12 Novo Nordisk A/S
• 10.13 Regeneron Pharmaceuticals, Inc.
• 10.14 Sanofi
• 10.15 Teva Pharmaceutical Industries Limited